Accelerated Biological Aging is Associated With Increased Risk of T2DM in the MASLD Population

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age20-90
SponsorNingbo No. 1 Hospital

About this trial

The association between biological aging and type 2 diabetes mellitus (T2DM) incidence in individuals with and without metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear.We assessed biological age by calculating phenotypic age (PhenoAge), Klemera-Doubal method (KDMAge), and homeostatic dysregulation (HDAge). To examine the association of biological ageing with the risk of T2DM, cox regression models were conducted. Furthermore, we applied survival analysis, restricted cubic spline models and population attributable fraction (PAF) to further evaluate the association between biological ageing and T2DM incidence.

Eligibility criteria

Qualifiers

Abdominal ultrasound data available in annual health check-up records

Disqualifiers

Age <20 or >90 years

Other causes of hepatic steatosis (e.g., alcoholic liver disease or hepatitis B infection)

Type 2 diabetes mellitus at baseline

Missing baseline data for any of the following variables: systolic blood pressure, albumin, alkaline phosphatase, blood urea nitrogen, creatinine, glycated hemoglobin (HbA1c), total cholesterol, lymphocyte percentage, white blood cell count, mean corpuscular volume, uric acid, fasting plasma glucose, and red cell distribution width (RDW)

Trial design

Treatments tested in this trial

  • Observational

Treatment groups

2,720 Participants
are divided into 2 treatment groups

Sponsors and collaborators